SCL Health Cancer Centers of Colorado - Lutheran Medical Center

Summary

SCL Health Cancer Centers of Colorado - Lutheran Medical Center is a medical facility located in Golden, Colorado. This center is recognized for care of Breast Cancer, Colon Cancer, Breast cancer, Skin Cancer, Esophageal Adenocarcinoma and other specialties. SCL Health Cancer Centers of Colorado - Lutheran Medical Center is involved with conducting 14 clinical trials across 43 conditions. There are 5 research doctors associated with this hospital, such as Marwan Massouh, Karng S. Log, Ian Gallaher, and Julie A. Carlson.

Top PIs

Clinical Trials running at SCL Health Cancer Centers of Colorado - Lutheran Medical Center

Breast Cancer

Esophageal cancer

Breast cancer

Esophageal Adenocarcinoma

Gastric cancer

Gastroesophageal Junction Adenocarcinoma

Esophageal Cancer

Stomach Cancer

Gliosarcoma

Glioblastoma

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria